Friday, June 19, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

BayWa’s Revenue Plunges 34% as Legal Probes Mount and Creditors Circle Ahead of Autumn Deadline

Jackson Burston by Jackson Burston
June 19, 2026
in Analysis, Earnings, MDAX & SDAX, Turnaround
0
BayWa Stock
0
SHARES
3
VIEWS
Share on FacebookShare on Twitter

BayWa’s first-quarter revenue collapsed 34% to €2.3 billion, deepening the crisis for the embattled German agribusiness group as it juggles a growing list of legal investigations, creditor write-downs, and a standstill agreement that expires this autumn. The shares closed at €10.65 on Thursday, down nearly 37% since the start of the year and more than 55% from the 52-week high of €23.90 reached in early December 2025. The 12-month slide amounts to a loss of over 46%.

The most immediate drag on turnover came from the sale of the Cefetra Group, but the company also cited poor weather, weak construction activity, and customer hesitation stemming from the broader restructuring uncertainty. The full-year accounts for 2025 have been delayed while the rescue plan is reworked; an auditor will not sign off until the new framework is ready.

BayWa’s legal troubles are escalating on three fronts. The Tübingen law firm TILP is preparing damages claims for shareholders who bought stock between January 2022 and January 2026, citing a BaFin order that found the company omitted material details about a billion-euro loan and the refinancing risks of a €500 million bond in its 2023 management report. Separately, the Munich public prosecutor’s office is investigating former chief executive Klaus Josef Lutz for breach of trust; investigators searched his private home in January 2026. Lutz is cooperating fully with the authorities, a spokesman said, and the presumption of innocence applies. A third inquiry, by the German audit oversight body Apas, targets PricewaterhouseCoopers. BayWa has already put the audit mandate out to tender and plans to propose KPMG for the 2026 accounts.

The creditor side is equally grim. Cooperative primary banks in Bavaria wrote down 60% of their promissory note loan in the 2024 accounts, a hit of €132 million. The regional cooperative association now recommends further impairments; in a worst-case scenario, the entire three-digit-million-euro loan could be written off. The standstill agreement with lenders runs until autumn 2026, which one Austrian creditor, RAI, described as demanding “very rapid, robust results” from the group. The financing gap stands at €2.7 billion.

Should investors sell immediately? Or is it worth buying BayWa?

The restructuring plan, due to be finalized by mid-2026, targets €4 billion in deleveraging by 2028 — roughly one-third has been achieved so far. It envisages creditor concessions of around €1 billion, the elimination of about 1,300 jobs, and a reduction in annual revenue to €10 billion. The company is racing to present a convincing update before the autumn deadline.

On the operational front, the agricultural trading arm is trying to project business as usual. At the DLG field days in Bernburg from 16 to 18 June, BayWa showcased its latest seed, crop protection, and sustainable farming systems at stand D32, touting just-in-time delivery of fertilisers and crop protection products to farms in northern, eastern, and central Germany. The company runs its own variety trials and experimental fields, and the slogan “Pflanzenbau out of the Box” was meant to reassure farmers that the core competence remains intact. But the market is not buying the narrative.

The stock’s technical indicators paint a bleak picture. The 200-day moving average of €15.42 and the 50-day average of €13.08 both stand far above the current price, signifying a complete detachment from historical valuation levels. The 30-day annualised volatility has surged to 86%, while the relative strength index sits at 35.6 — deep into oversold territory, yet no sustainable recovery has emerged. Every piece of bad news — whether from the courts, the auditor, or the trading floor — threatens to erode the already fragile confidence further, leaving BayWa in a race against time to seal a rescue before the autumn ultimatum arrives.

Ad

BayWa Stock: Buy or Sell?! New BayWa Analysis from June 19 delivers the answer:

The latest BayWa figures speak for themselves: Urgent action needed for BayWa investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 19.

BayWa: Buy or sell? Read more here...

Tags: BayWa
Jackson Burston

Jackson Burston

Related Posts

Vital Farms Stock
Analysis

Vital Farms Faces Twin Storms: Legal Investigation and Institutional Flight

June 19, 2026
Kuros Biosciences Stock
Analysis

Kuros Biosciences: Revenue Surges 72% But Shares Sink to 52-Week Low

June 19, 2026
CEREBRAS SYSTEMS INC - A Stock
AI & Quantum Computing

Cerebras Races Into First Earnings Report After Back-to-Back Double-Digit Gains

June 19, 2026
Next Post
Oracle Stock

Inside Oracle's Cash-Burning Engine: Record Demand, a $3 Billion Deal That Got Away, and a $40 Billion Capital Plea

Vulcan Energy Stock

Vulcan Energy’s Dual Narrative: Political Presence Meets Execution Demands

IBM Stock

IBM Navigates an AI Identity Crisis: Consultancy Gains Under Threat as Software Push Accelerates

Recommended

Tyler Stock

Institutional Investors Recalibrate Stakes in Government Software Provider

5 months ago
Trinet Stock

Trinet Stock: A Study in Contradictions Amid Steep Decline

10 months ago
Strategy Stock

Conflicting Signals Leave Strategy Investors at a Crossroads

9 months ago
Vulcan Energy Stock

Vulcan Energy Powers Europe’s Lithium Independence Drive

7 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Kuros Biosciences: Revenue Surges 72% But Shares Sink to 52-Week Low

Medtronic’s Asian Push and Portfolio Reshuffle Fail to Lift Stock from Its Lows

Cerebras Races Into First Earnings Report After Back-to-Back Double-Digit Gains

Outlook Therapeutics’ July 16 Shareholder Vote to Decide Nasdaq Fate as FDA Decision Looms on July 29

XPeng’s X9 Dominates Norwegian Range Test, but European Launch Fails to Ignite Stock

ServiceNow’s Q1 Revenue Jumps 22% as AI Bet Pays Off, but Armis Price Tag Weighs on Margins

Trending

Rocket Lab USA Stock
Industrial

Rocket Lab’s New Phase: Index Entry and Robotics M&A Converge to Reshape the Investment Thesis

by Rodolfo Hanigan
June 19, 2026
0

Monday will bring Rocket Lab a structural shift that no single launch can match. The stock joins...

Vital Farms Stock

Vital Farms Faces Twin Storms: Legal Investigation and Institutional Flight

June 19, 2026
Core Lithium Stock

Core Lithium’s Twin Catalyst: A$290M Funding and Bynoe Acquisition Target 2026 Production

June 19, 2026
Kuros Biosciences Stock

Kuros Biosciences: Revenue Surges 72% But Shares Sink to 52-Week Low

June 19, 2026
Medtronic Stock

Medtronic’s Asian Push and Portfolio Reshuffle Fail to Lift Stock from Its Lows

June 19, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Rocket Lab’s New Phase: Index Entry and Robotics M&A Converge to Reshape the Investment Thesis
  • Vital Farms Faces Twin Storms: Legal Investigation and Institutional Flight
  • Core Lithium’s Twin Catalyst: A$290M Funding and Bynoe Acquisition Target 2026 Production

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com